Drug profile

The FDA adverse-event record for Keppra

182 FDA reports name Keppra, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#561 of 2,679
by report volume (all drugs)
182
adverse-event reports
28.0%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Keppra ranks #561 of 2679 by total reports (182) and #136 of 1130 by death-coded share (28.0%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#561
This drug, reports of 2679
#136
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Keppra has 182 reports now versus 181 in that prior snapshot: 1 more (0.6%).

Report change
+1
Death-coded reports
+0
Death-coded share
−0.2 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Keppra changes

Signature read: death-coded report count at 51 is the most distinctive stamp on Keppra's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
182
Total Reports
51
Deaths Reported
28.0%
Death-coded share of reports

Active Ingredients

Keppra

Administration Routes

UnknownOralIntravenous

Species Affected

Dog 176
Cat 6

Most Affected Breeds

Retriever - Labrador 18
Crossbred Canine/dog 9
Shepherd Dog - German 9
Retriever - Golden 9
Chihuahua 8
Terrier - Bull - American Pit 8
Siberian Husky 7
Terrier - Yorkshire 6
Shih Tzu 6
Beagle 5

Most Reported Reactions

Seizure NOS 98
Death by euthanasia 35
Diarrhoea 18
Ataxia 16
Lethargy (see also Central nervous system depression in Neurological) 16
Death 15
Elevated alanine aminotransferase (ALT) 13
Vomiting 12
Not eating 11
Limb weakness 11
Behavioural disorder NOS 11
Urinary tract infection 11

Outcome Breakdown

Ongoing
99 (54.4%)
Euthanized
35 (19.2%)
Outcome Unknown
16 (8.8%)
Recovered/Normal
16 (8.8%)
Died
16 (8.8%)

Keppra: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Keppra, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar report volume

Nearest other drugs by FDA report count (182 here).

Similar death-coded share

Nearest other drugs by death-coded share (28.0% here), distinct from the volume row.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Keppra (#561 of 2,679 by report volume); death-coded 28.0%. PlainBreed drug row · death-coded report count stamp 51 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →